Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

Get Premium

Register

Sign In

EUR/USD

1.2217

-0.0019

-0.16%

GBP/USD

1.3852

-0.0040

-0.29%

USD/JPY

110.83

-0.1945

-0.18%

USD/CHF

0.9640

0.0051

0.53%

EUR/GBP

0.8820

0.0012

0.14%

USD/CAD

1.2498

0.0088

0.71%

NZD/USD

0.7275

-0.0019

-0.27%

EUR/JPY

135.41

-0.4460

-0.33%

EUR/CHF

1.1779

0.0046

0.39%

Aclaris Therapts Cmn

NASDAQ: ACRSHealthcare / Biotechnology / USA
24.40+0.14+0.58%Vol 317 9381Y Perf -12.07%
Jan 19th, 2018 16:00
BID20.45 ASK25.34
Open24.38 Previous Close24.26
Pre-Market- After-Trading24.40
 - -%  - -%
Target Price
46.67 
Analyst Rating
Strong Buy 1.00
Potencial %
91.27 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/100/100 
Income Ranking
 —    -
Market Cap (mil)752 
Earnings Rating
Price Range Ratio 52wk %
25.82 
Earnings Date

Today's Price Range

23.8724.81

 

52wk Range

21.3233.25

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
2.69%
3 Months
-8.37%
6 Months
-15.69%
1 Year
-12.07%
3 Years
-
5 Years
-
Last Quotes
Name / TickerPriceChg.Chg.%
ACRS24.400.14000.58
AAPL178.46-0.8000-0.45
GOOG1 137.517.72000.68
MSFT90.00-0.1000-0.11
XOM87.15-0.2800-0.32
WFC64.220.27000.42
JNJ147.360.44000.30
FB181.291.49000.83
GE16.26-0.5100-3.04
JPM113.01-0.2500-0.22
...

TickerPriceChg.%52 Week High
MAT16.145.9831.60
HBI23.205.4525.73
NKE67.214.8467.24
KSS67.544.1567.55
UA12.853.8826.25
PM108.923.66123.55
LOW104.953.54105.60
WYN126.993.47127.96
LB50.693.4163.10
PBCT20.083.3520.12
FL50.213.3377.86
AMG212.003.25213.86
HCA93.013.2293.32
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 22.90
Current Ratio 23.40
Long Term Debt to Total Capital -
Total Debt to Equity -
Interest Coverage -
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin33.80
EBIT Margin-6 868.60
EBITDA Margin-6 836.30
Pre-tax Profit Margin-
Profit Margin-
ValuationValueIndustryS&P 500US Markets
PE Ratio -
PB Ratio 3.16
PS Ratios 1 149.99
Price to Cash Flow -
Price to Free Cash Flow -16.50
Cash Flow Per Share -1.70
Price to Tangible Book3.53
Book Value per Share7.92
Enterprise Value (in ths.)543 019
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-
ROE last 12 Months -35.08
Return on Assets (5Y Avg) -
ROA last 12 Months -32.85
Return on Capital (5Y Avg) -
ROC last 12 Months -35.08
Return on invested Capital Q -8.82
Return on invested Capital Y-36.70
Assets Turnover0.00
Receivables Turnover2.10
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)684
Revenue per Share 0.02
Revenue Growth 3 Years -
Revenue Growth 5 Years -
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q03 2017-0.86-0.6326.74
Q02 2017-0.68-0.5617.65
Q01 2017-0.54-0.4811.11
Q04 2016-0.59-0.4916.95
Q03 2016-0.68-0.5026.47
Q02 2016-0.61-0.62-1.64
Q01 2016-0.50-0.65-30.00
Q04 2015-0.40-0.2830.00
Earnings Per EndEstimateRevision %Trend
12/2017 QR-0.9021.74Positive
12/2017 QR-1.15-2.68Negative
12/2017 FY-2.5916.45Positive
12/2018 FY-4.37-27.41Negative
Next Report Date7th Nov 2017
Estimated EPS Next Report-0.89
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume317 938
Shares Outstanding (in ths.)30 830
Trades Count1 738
Dollar Volume5 368 138
Avg. Volume308 664
Avg. Weekly Volume333 888
Avg. Monthly Volume308 437
Avg. Quarterly Volume355 999

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

69%31%

Bearish Bullish

66%34%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

There are no comments yet.

News

x